Shopping Cart
- Remove All
- Your shopping cart is currently empty
CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $129 | In Stock | |
10 mg | $198 | In Stock | |
25 mg | $455 | In Stock | |
50 mg | $787 | In Stock | |
100 mg | $1,280 | In Stock | |
1 mL x 10 mM (in DMSO) | $143 | In Stock |
Description | CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis. |
Targets&IC50 | PKCβII:0.41 mM, PKCβI:3.8 mM |
In vitro | In A10 cells, CGP-53353 (DAPH-7) inhibits glucose-induced cell proliferation when administered at 1 μM for 48-96 hours[1]. At a concentration of 1 μM for the initial 0-48 hours, CGP-53353 inhibits the glucose-induced increase and acceleration of DNA synthesis in A10 cells. It also blocks the glucose-induced increase in the percentage of S-phase cells[1]. |
Alias | DAPH-7 |
Molecular Weight | 365.33 |
Formula | C20H13F2N3O2 |
Cas No. | 145915-60-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: < 7.31 mg/mL DMSO: 50 mg/mL (136.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.